



Nasal decolonization in total joint arthroplasty: current state of evidence

Andrea Zampoli^{1,2,4}, Ghazal Pourbozorg^{3,4}, Goksel Dikmen⁴, Ibrahim Tuncay⁴, and Javad Parvizi⁴

¹Operative Research Unit of Orthopaedic and Trauma Surgery,
Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy

²Research Unit of Orthopaedic and Trauma Surgery,
Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy

³International Consensus Meeting (ICM), Department of Orthopedics and Trauma Surgery, University Medical
Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, 24105 Kiel, Germany

⁴International Joint Center, Acibadem University Hospital, Istanbul, Türkiye

Correspondence: Javad Parvizi (javadparvizi@gmail.com)

Received: 2 March 2026 – Revised: 1 May 2026 – Accepted: 6 May 2026 – Published: 22 May 2026

Abstract. Periprosthetic joint infection is a major cause of morbidity and economic cost after total joint arthroplasty, with *Staphylococcus aureus* consistently identified as the most common pathogen causing surgical site infection (SSI) and periprosthetic joint infections (PJIs). Nasal mucosa is one of the principle reservoirs for *S. aureus*. Molecular epidemiology investigations have found concordance between nasal organisms and infecting strains, implying that many postoperative infections arise endogenously. Over the last decade, various clinical trials, institutional protocols, and meta-analyses have evaluated the efficacy of nasal screening and decolonization of *Staph aureus*. Recent evidence suggests that the success of infection prevention procedures is dependent on the reliability and consistency of decolonization rather than screening alone. This narrative review summarizes current evidence on nasal decolonization in total joint arthroplasty, including epidemiological data, methods of screening, and accessible therapy choices to suggest practical and reproducible infection control measures.

1 Background

Periprosthetic joint infection (PJI) is a devastating complication following total hip and knee arthroplasty, resulting in considerable morbidity and economic burden (Parvizi et al., 2010). While multiple patient- and procedure-related factors contribute to infection risk in elective orthopaedic surgery, identifying modifiable risk factors remains central to prevention efforts (Kunutsor et al., 2016). *Staphylococcus aureus*, encompassing both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains, is the predominant pathogen implicated in surgical site infections (SSIs) and PJIs after total joint arthroplasty (TJA) (Skråmm et al., 2014). Nasal colonization serves as the primary reservoir for *S. aureus*, and molecular typing studies indicate that most postoperative infections originate from the patient's endogenous nasal flora. Approximately 20%–30% of patients scheduled for elective orthopaedic procedures are colonized with *Staph*

aureus, which increases the likelihood of postoperative infection (Stambough et al., 2017; Zhu et al., 2020). Importantly, nasal carriage constitutes a modifiable risk factor. Multiple clinical studies (Ribau et al., 2021a; Stambough et al., 2017; Zhu et al., 2020), institutional protocols, and systematic reviews have demonstrated that preoperative *S. aureus* screening and nasal decolonization are associated with reduced risks of SSI and, in some instances, PJI following TJA. Ribau et al. (2021a) demonstrated that, in elective TJA, lack of preoperative nasal decolonization significantly increased the risk of *S. aureus* infection (RR = 2.18 ± 0.41). Despite accumulating evidence supporting these interventions, uncertainties persist regarding optimal patient selection, screening techniques, decolonization regimens, timing and duration of therapy, agent choice, and integration into standard arthroplasty care pathways. This narrative review synthesizes current evidence on nasal decolonization in TJA and outlines a

pragmatic, decision-focused approach for clinical implementation.

2 Correlation between nasal colonization and infection after TJA

S. aureus infection is associated with prolonged hospitalizations, increased mortality, higher healthcare costs, and a higher risk of readmission within 1 year after total hip and knee arthroplasty (De Buys et al., 2023; Weiser and Moucha, 2015). Approximately 4 % of patients undergoing total hip or knee arthroplasty require hospital readmission within 1 year because of infectious complications (Zawadzki et al., 2017). *S. aureus* represents the leading pathogen across the spectrum of postoperative infections after TJA (Weinstein et al., 2023). Analyses derived from large national surveillance systems, including data from the Centres for Disease Control and Prevention (CDC) (National Healthcare Safety Network) (NHSN) (UK Health Security Agency, 2026), indicate that *Staphylococcus aureus* accounts for approximately 60 %–63 % of deep SSIs and PJI following hip and knee replacement. According to the UK's yearly national surveillance report (UK Health Security Agency, 2026), *Staphylococcus aureus* is the most common cause of postoperative infections. MSSA accounts for around 17.2 % of confirmed cases, while MRSA accounts for approximately 2.4 %, demonstrating its continued importance despite geographical disparities in rates. Molecular typing studies consistently reveal a high degree of genetic concordance between nasal carriage and infecting *S. aureus* isolates in orthopaedic surgery. These findings support the hypothesis that most postoperative *Staphylococcus* infections originate endogenously (Ma et al., 2022; Piewngam and Otto, 2024; Troeman et al., 2023).

Nasal colonization is a modifiable patient-related risk factor in elective TJA and can be effectively addressed through standardized preoperative screening and decontamination protocols. Several studies (Bianco Prevot et al., 2024; Lin et al., 2021) have demonstrated that patients undergoing nasal decolonization experience a lower incidence of postoperative SSI and a reduced rate of PJI compared to untreated control groups.

3 Screening and decolonization versus universal decolonization for patients undergoing TJA

Preoperative screening for *S. aureus* is best regarded as an implementation-dependent strategy rather than a universal requirement in TJA. Screening for MRSA prior to elective orthopaedic surgery may constitute sound clinical practice when informed by local epidemiological data. The 2024 ESCMID guidelines (Righi et al., 2024) limit this recommendation to centres where screening is feasible and timely, allowing results to be returned early enough to guide decolonization without delaying surgery. Furthermore, the guide-

line indicates that current evidence does not support screening as an isolated intervention to reduce SSI caused by *S. aureus* but instead recommends its use as part of a combined screen-and-treat protocol. Similarly, the 2025 International Consensus Meeting (ICM) (Yildiz et al., 2025) found no evidence to indicate that universal MRSA screening conferred much clinical benefit in reducing SSI/PJI after major orthopaedic procedures. Consequently, the decision between targeted and universal screening should be tailored to local MRSA prevalence, laboratory turnaround times, and the ability to incorporate results into immediate perioperative management. A screen-and-treat strategy limits decolonization to documented carriers, avoiding unnecessary treatment in non-colonized patients. However, culture-based screening requires adequate turnaround time, while rapid molecular assays may reduce delays but remain limited by cost and workflow constraints. Current evidence indicates that the clinical benefit of preoperative infection prevention strategies in TJA derives primarily from nasal decolonization itself rather than from screening. While the protective effect of decolonization in TJA is well established, the optimal implementation strategy of targeted decolonization based on screening versus universal decolonization remains less clearly defined in the orthopaedic literature. Stambough et al. (2017) compared a screen-and-treat strategy with a universal decolonization approach in patients undergoing TJA, demonstrating a significant reduction in both 90 d overall infections and *S. aureus* infections in the universal decolonization group. Cost analysis indicated net savings exceeding USD 700 000 in the universal decolonization group. Additionally, Kerbel et al. (2018) assessed economic thresholds for cost-effectiveness and found that screen-and-treat treatment strategies require substantially higher absolute risk reductions to be cost-effective compared to universal decolonization protocols. A recent systematic review and meta-analysis by Ribau et al. (2021b) found that universal decolonization is both the most cost-effective strategy and the most effective at reducing PJI. This approach also eliminates the risk of untreated carriers resulting from limitations in screening sensitivity or delays in result availability. Nevertheless, the universal use of topical antibiotics raises concerns about the potential emergence of mupirocin resistance, an issue that most economic models do not fully address (Hetem et al., 2016). To reduce this risk, antiseptic alternatives such as octenidine or intranasal povidone-iodine have been proposed and are increasingly implemented (Hammond et al., 2023; Abolghasemi et al., 2025; Anderson et al., 2015). In alignment with this evidence, the ICM 2025 (Yildiz et al., 2025) recommends routine nasal decolonization for all patients undergoing major orthopaedic procedures, preferably utilizing a non-antibiotic antiseptic agent.

4 Options for nasal decolonization

Intranasal mupirocin has been the primary topical antibacterial agent for nasal decolonization, demonstrating activity against *Staphylococci* and *Streptococci* (Ward and Campoli-Richards, 1986). Prior studies have shown that intranasal mupirocin significantly reduces nasal *S. aureus* burden, supporting its inclusion in decolonization protocols (Perl et al., 2002). Standard regimens recommend 2% mupirocin applied to the anterior nares twice daily for 5 d (Septimus, 2019). Despite high initial efficacy, recolonization or persistence of colonization is common when mupirocin is used. Several studies report elimination of nasal *S. aureus* in 91% of treated patients within 96 h, but recurrence rates exceed 50% within 2 to 6 months (Baede et al., 2022; Fernandez et al., 1995; Septimus, 2019). Decolonization failure is closely linked to mupirocin resistance, as resistant strains are more likely to persist despite topical therapy, while susceptible strains are more likely to be eradicated in the short term (Patel et al., 2009; Premanand et al., 2023). Reported resistance rates are approximately 10% in *S. aureus* and 15% in MRSA, yet routine resistance testing is infrequent (Fouad et al., 2019; Jones et al., 2007; Rudresh et al., 2015). The CDC (Centers for Disease Control and Prevention, 2026) recommends chlorhexidine gluconate (CHG) wash as an adjunct to mupirocin to reduce bacterial load at extra-nasal sites. Alternative topical agents, such as neomycin or fusidic acid, have been proposed, but comparative clinical evidence remains limited (Smith and Herwaldt, 2023). In TJA, iodine- or chlorhexidine-based agents are recommended to support decolonization and minimize the risk of antibiotic resistance (Fernández-Rodríguez et al., 2024; Righi et al., 2024). Non-antibiotic topical agents have also been investigated as alternative strategies for nasal decolonization. Povidone-iodine (PVP-I) demonstrates broad antimicrobial activity against Gram-positive and Gram-negative bacteria, including MSSA and MRSA (Septimus, 2019). Early in vitro studies identified PI as a potential alternative to mupirocin, although nasal secretions can reduce its antimicrobial efficacy (Hill and Casewell, 2000). In a randomized, placebo-controlled trial, Rezapoor et al. (2017) found that a 5% PVP-I-based nasal antiseptic achieved significantly greater *S. aureus* decolonization at 4 h compared to off-the-shelf PVP-I ($P = 0.003$). Phillips et al. (2014) compared intranasal mupirocin with PVP-I in patients undergoing TJA and spine surgery. Although postoperative culture negativity was higher with mupirocin than with PVP-I (92% vs. 54%), the per-protocol analysis showed that *S. aureus* deep SSI occurred in 5 of 763 procedures in the mupirocin group and in 0 of 776 procedures in the PVP-I group ($P = 0.03$). Similarly, Ghaddara et al. (2020) showed that a single intranasal application of 10% PVP-I significantly reduced MRSA colony counts at 1 to 6 h, but the effect was not sustained at 12 to 24 h. Current evidence supports nasal PVP-I as a well-tolerated, non-antibiotic alternative for perioperative SSI prevention,

with its primary benefit limited to the immediate preoperative period rather than long-term decolonization (Septimus, 2019; Smith and Herwaldt, 2023). This limitation has prompted interest in broader, resistance-free techniques suitable for general use. Alcohol-based nasal antiseptics offer a non-antibiotic decolonization strategy with rapid-onset, broad antimicrobial activity, and no risk of resistance (Hoffmann et al., 2024). Hoffmann et al. (2024) confirmed bactericidal activity against Gram-positive, Gram-negative, and fungal organisms, supporting a microbiome-modulating approach. Randomized trials (Kanwar et al., 2019; Steed et al., 2014) indicate that a single dose provides only transient suppression, while repeated dosing is necessary to maintain bacterial reduction. Clinical studies have demonstrated that alcohol-based antiseptics, when used perioperatively or postoperatively, is associated with reduced SSI rates, including TJA populations, with high adherence and favourable safety profiles (Bostian et al., 2023; Mullen et al., 2017). A meta-analysis by Hoffmann et al. (2024) found that alcohol-based antiseptic was more effective than mupirocin- and iodophor-based agents in preventing SSIs, with superior outcomes compared to mupirocin (OR ≈ 4.1) and iodophors (OR ≈ 3.0). Retapamulin, a topical pleuromutilin antibiotic active against MSSA and MRSA, has been evaluated as a salvage agent in mupirocin-resistant carriers. A randomized, placebo-controlled trial reported higher short-term decolonization rates, but the effect was not durable, limiting its use to selected cases (Patel et al., 2019).

5 Conclusions

Nasal colonization with *S. aureus* is a significant risk factor for postoperative infections following TJA. However, management strategies remain inconsistent. Clinical experience and implementation studies indicate that universal decolonization has a greater impact on preventative effectiveness than screening. Targeted screening may be appropriate in high-volume institutions with access to rapid tests, but logistical problems, delays in delivering test results, and false-negative results are serious disadvantages of screening. Thus, universal decolonization is a more practical and reliable option. Intranasal mupirocin is still effective in reducing nasal bacterial load, but the rise in resistance detracts from the efficacy of this agent. Based on the above information, the following key principles may be considered for patients undergoing arthroplasty:

- Universal nasal decolonization should be established as a standard component of infection prevention protocols for all patients, rather than being applied sporadically or at the discretion of individual clinicians.
- Although mupirocin has been shown to be an effective decolonization agent, due to rising resistance and antimicrobial stewardship, consideration should be given

to non-antibiotic antiseptic agents for universal decolonization.

Data availability. No original research data were generated or analyzed in this study. All data and evidence discussed in this narrative review are derived from previously published articles cited in the reference list. Therefore, no additional dataset is available for deposition in a public repository.

Author contributions. Andrea Zampoli: writing – review and editing, writing – original draft, supervision, methodology, formal analysis, conceptualization. Ghazal Pourbozorg: writing the review and editing, writing the original draft, methodology, investigation, formal analysis. Goksel Dikmen: writing the review and editing, writing the original draft, supervision, formal analysis, conceptualization. Ibrahim Tuncay: writing – review and editing, supervision, formal analysis, conceptualization. Javad Parvizi: writing – review and editing, supervision, formal analysis, conceptualization.

Competing interests. The contact author has declared that none of the authors has any competing interests.

Ethical statement. Ethical approval and informed consent were not required for this study because it is a narrative review based on previously published literature and did not involve human participants, animals, or identifiable patient data.

Disclaimer. Publisher's note: Copernicus Publications remains neutral with regard to jurisdictional claims made in the text, published maps, institutional affiliations, or any other geographical representation in this paper. The authors bear the ultimate responsibility for providing appropriate place names. Views expressed in the text are those of the authors and do not necessarily reflect the views of the publisher.

Review statement. This paper was edited by Marta Sabater-Martos and reviewed by two anonymous referees.

References

- Abolghasemi, S., Ghazi, M., Ziaie, S., Mahboubi, A., Gachkar, L., Keyvanfar, A., and Naeimipoor, M.: Comparison of the Efficacy of Povidone-Iodine with Mupirocin in Decolonizing *Staphylococcus aureus* from the Nasal Cavity of Healthcare Workers: A Single-Blinded Randomized Controlled Trial, *Infect. Disord. Drug Targets*, 25, e18715265301671, <https://doi.org/10.2174/0118715265301671240910070901>, 2025.
- Anderson, M. J., David, M. L., Scholz, M., Bull, S. J., Morse, D., Hulse-Stevens, M., and Peterson, M. L.: Efficacy of Skin and Nasal Povidone-Iodine Preparation against Mupirocin-

Resistant Methicillin-Resistant *Staphylococcus aureus* and *S. aureus* within the Anterior Nares, *Antimicrob. Agents Ch.*, 59, 2765–2773, <https://doi.org/10.1128/AAC.04624-14>, 2015.

- Baede, V. O., Barray, A., Tavakol, M., Lina, G., Vos, M. C., and Rasigade, J.-P.: Nasal microbiome disruption and recovery after mupirocin treatment in *Staphylococcus aureus* carriers and non-carriers, *Sci. Rep.*, 12, 19738, <https://doi.org/10.1038/s41598-022-21453-4>, 2022.
- Bianco Prevot, L., Tansini, L., Riccardo, A., Bolcato, V., Tronconi, L. P., and Basile, G.: Cutting Periprosthetic Infection Rate: *Staphylococcus aureus* Decolonization as a Mandatory Procedure in Preoperative Knee and Hip Replacement Care – Insights from a Systematic Review and Meta-Analysis of More Than 50,000 Patients, *J. Clin. Med.*, 13, 4197, <https://doi.org/10.3390/jcm13144197>, 2024.
- Bostian, P. A., Vaida, J., Brooks, W. C., Chaharbakshi, E., Dietz, M. J., Klein, A. E., Murphy, T. R., Frye, B. M., and Lindsey, B. A.: A Novel Protocol for Nasal Decolonization Using Prolonged Application of an Alcohol-Based Nasal Antiseptic Reduces Surgical Site Infections in Total Joint Arthroplasty Patients: A Retrospective Cohort Study, *Surg. Infect. (Larchmt)*, 24, 651–656, <https://doi.org/10.1089/sur.2022.344>, 2023.
- Centers for Disease Control and Prevention: CDC/NHSN Surveillance Definitions for Specific Types of Infections, National Healthcare Safety Network Patient Safety Component Manual, Chapter 17, Centers for Disease Control and Prevention, Atlanta, GA, https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf (last access: 19 May 2026), 2026.
- De Buys, M., Moodley, K., Cakic, J. N., and Pietrzak, J. R. T.: *Staphylococcus aureus* colonization and periprosthetic joint infection in patients undergoing elective total joint arthroplasty: a narrative review, *EFORT Open Reviews*, 8, 680–689, <https://doi.org/10.1530/EOR-23-0031>, 2023.
- Fernandez, C., Gaspar, C., Torrellas, A., Vindel, A., Saez-Nieto, J. A., Cruzet, F., and Aguilar, L.: A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of *Staphylococcus aureus* among hospital personnel, *J. Antimicrob. Chemoth.*, 35, 399–408, <https://doi.org/10.1093/jac/35.3.399>, 1995.
- Fernández-Rodríguez, D., Cho, J., Chisari, E., Citardi, M. J., and Parvizi, J.: Nasal microbiome and the effect of nasal decolonization with a novel povidone-iodine antiseptic solution: a prospective and randomized clinical trial, *Sci. Rep.*, 14, 16739, <https://doi.org/10.1038/s41598-023-46792-8>, 2024.
- Fouad, M., Omar, H., Hassan, W., and Hashem, A.: Mupirocin Resistance among Methicillin Resistant *Staphylococcus aureus* Causing Surgical Site Infections, *Egyptian Journal of Medical Microbiology*, 28, 65–71, <https://doi.org/10.21608/ejmm.2019.283216>, 2019.
- Ghaddara, H. A., Kumar, J. A., Cadnum, J. L., Ng-Wong, Y. K., and Donskey, C. J.: Efficacy of a povidone iodine preparation in reducing nasal methicillin-resistant *Staphylococcus aureus* in colonized patients, *Am. J. Infect. Control*, 48, 456–459, <https://doi.org/10.1016/j.ajic.2019.09.014>, 2020.
- Hammond, E. N., Kates, A. E., Putman-Buehler, N., Watson, L., Godfrey, J. J., Riley, C. N., Dixon, J., Brys, N., Haleem, A., Bentz, M. L., and Safdar, N.: Quality improvement study on the effectiveness of intranasal povidone-iodine decolo-

- nization on surgery patients, *Infect. Prev. Pract.*, 5, 100274, <https://doi.org/10.1016/j.infpip.2023.100274>, 2023.
- Hetem, D. J., Bootsma, M. C. J., and Bonten, M. J. M.: Prevention of Surgical Site Infections: Decontamination With Mupirocin Based on Preoperative Screening for *Staphylococcus aureus* Carriers or Universal Decontamination?, *Clin. Infect. Dis.*, 62, 631–636, <https://doi.org/10.1093/cid/civ990>, 2016.
- Hill, R. L. and Casewell, M. W.: The in-vitro activity of povidone-iodinecream against *Staphylococcus aureus* and its bioavailability in nasal secretions, *J. Hosp. Infect.*, 45, 198–205, <https://doi.org/10.1053/jhin.2000.0733>, 2000.
- Hoffmann, K. K., Steed, C. J., Kremelberg, D., and Wenzel, R. P.: The efficacy of an alcohol-based nasal antiseptic versus mupirocin or iodophor for preventing surgical site infections: A meta-analysis, *Am. J. Infect. Control*, 52, 1202–1208, <https://doi.org/10.1016/j.ajic.2024.07.003>, 2024.
- Jones, J. C., Rogers, T. J., Brookmeyer, P., Dunne, W. M., Storch, G. A., Coopersmith, C. M., Fraser, V. J., and Warren, D. K.: Mupirocin Resistance in Patients Colonized with Methicillin-Resistant *Staphylococcus aureus* in a Surgical Intensive Care Unit, *Clin. Infect. Dis.*, 45, 541–547, <https://doi.org/10.1086/520663>, 2007.
- Kanwar, A., Kumar, J. A., Ng-Wong, Y. K., Thakur, M., Cadnum, J. L., Alhmidi, H., Mana, T. S. C., Jencson, A. L., and Donskey, C. J.: Evaluation of an alcohol-based antiseptic for nasal decolonization of methicillin-resistant *Staphylococcus aureus* in colonized patients, *Infect. Cont. Hosp. Ep.*, 40, 1436–1437, <https://doi.org/10.1017/ice.2019.266>, 2019.
- Kerbel, Y. E., Sunkerneni, A. R., Kirchner, G. J., Prodrromo, J. P., and Moretti, V. M.: The Cost-Effectiveness of Preoperative *Staphylococcus aureus* Screening and Decolonization in Total Joint Arthroplasty, *J. Arthroplasty*, 33, S191–S195, <https://doi.org/10.1016/j.arth.2018.01.032>, 2018.
- Kunutsor, S. K., Whitehouse, M. R., Blom, A. W., Beswick, A. D., and INFORM Team: Patient-Related Risk Factors for Periprosthetic Joint Infection after Total Joint Arthroplasty: A Systematic Review and Meta-Analysis, *PLoS One*, 11, e0150866, <https://doi.org/10.1371/journal.pone.0150866>, 2016.
- Lin, L., Ke, Z.-Y., Wang, Y., Chen, X.-L., Zhong, D., and Cheng, S.: Efficacy of preoperative screening and decolonization for *staphylococcus aureus* in total joint arthroplasty: A meta-analysis, *Asian J. Surg.*, 44, 807–818, <https://doi.org/10.1016/j.asjsur.2020.12.037>, 2021.
- Ma, D., Brothers, K. M., Maher, P. L., Phillips, N. J., Simonetti, D., William Pasculle, A., Richardson, A. R., Cooper, V. S., and Urish, K. L.: *Staphylococcus aureus* genotype variation among and within periprosthetic joint infections, *J. Orthop. Res.*, 40, 420–428, <https://doi.org/10.1002/jor.25031>, 2022.
- Mullen, A., Wieland, H. J., Wieser, E. S., Spannhake, E. W., and Marinos, R. S.: Perioperative participation of orthopedic patients and surgical staff in a nasal decolonization intervention to reduce *Staphylococcus* spp. surgical site infections, *Am. J. Infect. Control*, 45, 554–556, <https://doi.org/10.1016/j.ajic.2016.12.021>, 2017.
- Parvizi, J., Pawasarat, I. M., Azzam, K. A., Joshi, A., Hansen, E. N., and Bozic, K. J.: Periprosthetic joint infection: the economic impact of methicillin-resistant infections, *J. Arthroplasty*, 25, 103–107, <https://doi.org/10.1016/j.arth.2010.04.011>, 2010.
- Patel, A., Shopsin, B., Stachel, A., and Lighter, J.: 568. A Randomized, Double-Blinded, Placebo-Controlled Trial of Retapamulin for Nasal and Rectal Decolonization of Mupirocin-Resistant Methicillin-Resistant *Staphylococcus aureus* Among Children, *Open Forum Infectious Diseases*, 6, S268–S269, <https://doi.org/10.1093/ofid/ofz360.637>, 2019.
- Patel, J. B., Gorwitz, R. J., and Jernigan, J. A.: Mupirocin resistance, *Clin. Infect. Dis.*, 49, 935–941, <https://doi.org/10.1086/605495>, 2009.
- Perl, T. M., Cullen, J. J., Wenzel, R. P., Zimmerman, M. B., Pfaller, M. A., Sheppard, D., Twombly, J., French, P. P., and Herwaldt, L. A.: Intranasal Mupirocin to Prevent Postoperative *Staphylococcus aureus* Infections, *N. Engl. J. Med.*, 346, 1871–1877, <https://doi.org/10.1056/NEJMoa003069>, 2002.
- Phillips, M., Rosenberg, A., Shopsin, B., Cuff, G., Skeete, F., Foti, A., Kraemer, K., Inglima, K., Press, R., and Bosco, J.: Preventing surgical site infections: a randomized, open-label trial of nasal mupirocin ointment and nasal povidone-iodine solution, *Infect. Cont. Hosp. Ep.*, 35, 826–832, <https://doi.org/10.1086/676872>, 2014.
- Piewngam, P. and Otto, M.: *Staphylococcus aureus* colonisation and strategies for decolonisation, *Lancet Microbe*, 5, e606–e618, [https://doi.org/10.1016/S2666-5247\(24\)00040-5](https://doi.org/10.1016/S2666-5247(24)00040-5), 2024.
- Premanand, B., Thiyagarajan, S., Thangavelu, S., Mohammed Ali, S., and George, F. S. A.: Prevalence of Mupirocin and Methicillin-Resistant *Staphylococcus aureus* in Nasal Carriage Among Healthcare Workers in an Intensive Care Unit and Post-decolonization Screening Outcomes at a Tertiary Care Hospital: A Prospective Study, *Cureus*, <https://doi.org/10.7759/cureus.46435>, 2023.
- Rezapoor, M., Nicholson, T., Tabatabaee, R. M., Chen, A. F., Maltenfort, M. G., and Parvizi, J.: Povidone-Iodine-Based Solutions for Decolonization of Nasal *Staphylococcus aureus*: A Randomized, Prospective, Placebo-Controlled Study, *J. Arthroplasty*, 32, 2815–2819, <https://doi.org/10.1016/j.arth.2017.04.039>, 2017.
- Ribau, A. I., Collins, J. E., Chen, A. F., and Sousa, R. J.: Is Preoperative *Staphylococcus aureus* Screening and Decolonization Effective at Reducing Surgical Site Infection in Patients Undergoing Orthopedic Surgery? A Systematic Review and Meta-Analysis With a Special Focus on Elective Total Joint Arthroplasty, *J. Arthroplasty*, 36, 752–766, <https://doi.org/10.1016/j.arth.2020.08.014>, 2021a.
- Ribau, A. I., Collins, J. E., Chen, A. F., and Sousa, R. J.: Is Preoperative *Staphylococcus aureus* Screening and Decolonization Effective at Reducing Surgical Site Infection in Patients Undergoing Orthopedic Surgery? A Systematic Review and Meta-Analysis With a Special Focus on Elective Total Joint Arthroplasty, *J. Arthroplasty*, 36, 752–766, <https://doi.org/10.1016/j.arth.2020.08.014>, 2021b.
- Righi, E., Mutters, N. T., Guirao, X., Dolores Del Toro, M., Eckmann, C., Friedrich, A. W., Giannella, M., Presterl, E., Christaki, E., Cross, E. L. A., Visentin, A., Sganga, G., Tsioutis, C., Tacconelli, E., and Kluytmans, J.: European Society of Clinical Microbiology and Infectious Diseases/European Committee on infection control clinical guidelines on pre-operative decolonization and targeted prophylaxis in patients colonized by multidrug-resistant Gram-positive bacteria before surgery, *Clin. Microbiol. Infect.*, 30, 1537–1550, <https://doi.org/10.1016/j.cmi.2024.07.012>, 2024.

- Rudresh, M. S., Ravi, G. S., Motagi, A., Alex, A. M., Sandhya, P., and Navaneeth, B. V.: Prevalence of Mupirocin Resistance Among Staphylococci, its Clinical Significance and Relationship to Clinical Use, *J. Lab. Physicians*, 7, 103–107, <https://doi.org/10.4103/0974-2727.163127>, 2015.
- Septimus, E. J.: Nasal decolonization: What antimicrobials are most effective prior to surgery?, *Am. J. Infect. Control*, 47S, A53–A57, <https://doi.org/10.1016/j.ajic.2019.02.028>, 2019.
- Skråmm, I., Fossum Moen, A. E., Årøen, A., and Bukholm, G.: Surgical Site Infections in Orthopaedic Surgery Demonstrate Clones Similar to Those in Orthopaedic Staphylococcus aureus Nasal Carriers, *J. Bone Joint Surg. Am.*, 96, 882–888, <https://doi.org/10.2106/JBJS.M.00919>, 2014.
- Smith, M. and Herwaldt, L.: Nasal decolonization: What antimicrobials and antiseptics are most effective before surgery and in the ICU, *Am. J. Infect. Control*, 51, A64–A71, <https://doi.org/10.1016/j.ajic.2023.02.004>, 2023.
- Stambough, J. B., Nam, D., Warren, D. K., Keeney, J. A., Clohisy, J. C., Barrack, R. L., and Nunley, R. M.: Decreased Hospital Costs and Surgical Site Infection Incidence With a Universal Decolonization Protocol in Primary Total Joint Arthroplasty, *J. Arthroplasty*, 32, 728–734, <https://doi.org/10.1016/j.arth.2016.09.041>, 2017.
- Steed, L. L., Costello, J., Lohia, S., Jones, T., Spannhake, E. W., and Nguyen, S.: Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic, *Am. J. Infect. Contr.*, 42, 841–846, <https://doi.org/10.1016/j.ajic.2014.04.008>, 2014.
- Troeman, D. P. R., Hazard, D., Timbermont, L., Malhotra-Kumar, S., van Werkhoven, C. H., Wolkewitz, M., Ruzin, A., Goossens, H., Bonten, M. J. M., Harbarth, S., Sifakis, F., Kluytmans, J. A. J. W., ASPIRE-SSI Study Team, Vlaeminck, J., Vilken, T., Xavier, B. B., Lammens, C., van Esschoten, M., Paling, F. P., Recanatini, C., Coenjaerts, F., Sellman, B., Tkaczyk, C., Weber, S., Ekkelenkamp, M. B., van der Laan, L., Vierhout, B. P., Couvé-Deacon, E., David, M., Chadwick, D., Llewellyn, M. J., Ustianowski, A., Bateman, A., Mawer, D., Carevic, B., Konstantinovic, S., Djordjevic, Z., Del Toro-López, M. D., Gallego, J. P. H., Escudero, D., Rojo, M. P., Torre-Cisneros, J., Castelli, F., Nardi, G., Barbadoro, P., Altmets, M., Mitt, P., Todor, A., Bubenek-Turconi, S.-I., Corneci, D., Sandesc, D., Gheorghita, V., Brat, R., Hanke, I., Neumann, J., Tomáš, T., Laffut, W., and Van den Abeele, A.-M.: Postoperative Staphylococcus aureus Infections in Patients With and Without Preoperative Colonization, *JAMA Netw. Open*, 6, e2339793, <https://doi.org/10.1001/jamanetworkopen.2023.39793>, 2023.
- UK Health Security Agency: Surveillance of surgical site infections in NHS hospitals in England: April 2024 to March 2025, UK Health Security Agency, London, <https://assets.publishing.service.gov.uk/media/69383a867a605b2d61cd8fa0/SSISS-annual-report-2024-to-2025.pdf> (last access: 19 May 2026), 2026.
- Ward, A. and Campoli-Richards, D. M.: Mupirocin: A Review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use, *Drugs*, 32, 425–444, <https://doi.org/10.2165/00003495-198632050-00002>, 1986.
- Weinstein, E. J., Stephens-Shields, A. J., Newcomb, C. W., Silibovskiy, R., Nelson, C. L., O'Donnell, J. A., Glaser, L. J., Hsieh, E., Hanberg, J. S., Tate, J. P., Akgün, K. M., King, J. T., and Lo Re, V.: Incidence, Microbiological Studies, and Factors Associated With Prosthetic Joint Infection After Total Knee Arthroplasty, *JAMA Netw. Open*, 6, e2340457, <https://doi.org/10.1001/jamanetworkopen.2023.40457>, 2023.
- Weiser, M. C. and Moucha, C. S.: The Current State of Screening and Decolonization for the Prevention of Staphylococcus aureus Surgical Site Infection After Total Hip and Knee Arthroplasty, *J. Bone Joint Surg. Am.*, 97, 1449–1458, <https://doi.org/10.2106/JBJS.N.01114>, 2015.
- Yildiz, F., Ng, M. K., Abbaszadeh, A., Lizcano, J. D., Alkhashki, H. M. I., Alzate, R., Bingham, J. S., Bos, K., Damioli, L. E., Del Toro, M. D., Fadel, M., Goncalves, S. R., Grenho, A., Higuera-Rueda, C. A., Hofstaetter, J., Inaba, Y., Incesoy, M. A., Kenanidis, E., Martinez, D., Mont, M. A., Morikane, K., Norambuena, G. A., Palacio, J. C., Parvizi, J., Pelt, C., Riaz, T., Schweitzer, D., Seidelman, J., Spangehl, M. J., Suleiman, L., Tarabichi, S., Uchiyama, K., and Yayac, M.: 2025 ICM: Decolonization, *J. Arthroplasty*, <https://doi.org/10.1016/j.arth.2025.10.096>, 2025.
- Zawadzki, N., Wang, Y., Shao, H., Liu, E., Song, C., Schoonmaker, M., and Shi, L.: Readmission due to infection following total hip and total knee procedures: A retrospective study, *Medicine*, 96, e7961, <https://doi.org/10.1097/MD.0000000000007961>, 2017.
- Zhu, X., Sun, X., Zeng, Y., Feng, W., Li, J., Zeng, J., and Zeng, Y.: Can nasal Staphylococcus aureus screening and decolonization prior to elective total joint arthroplasty reduce surgical site and prosthesis-related infections? A systematic review and meta-analysis, *J. Orthop. Surg. Res.*, 15, 60, <https://doi.org/10.1186/s13018-020-01601-0>, 2020.